Clinical landscape and mortality risk in Intensive Care Unit peritonitis in a low-MultiDrug Resistant setting: A multicentre cohort study
Authors' conclusion
Through this large cohort study of ICU patients with peritonitis, we observed a low prevalence of MDRO.
Study context
- Population
- Intensive care unit (ICU) patients diagnosed with intra-abdominal infection across 4 hospitals, 2020–2022
- Participants
- 392 patients · 4 hospitals
- Exposure
- Community vs early nosocomial vs late nosocomial peritonitis
- Community peritonitis (CP)n = 195
- Early nosocomial peritonitis (ENP)n = 88
- Late nosocomial peritonitis (LNP)n = 109
- Outcome
- Clinico-biological features and microbiological characteristics according to peritonitis setting
Methodological detailsmulticentre
- Multicentre
Main finding
As reported in the abstract
MDRO prevalence and distribution by setting
MDRO prevalence and distribution by setting
Cephalosporinase-producing bacteria CP 19.0% · LNP 40.4%
- LNP vs CP, ENP: P = 0.03
- LNP vs CP: P < 0.001
- Extended-spectrum beta-lactamase-producing bacteria, all patients
- 24 (6.1%)
- Carbapenem-resistant bacteria, all patients
- 5 (1.3%)
Observational data: associations, not effects.
Further findings
90-day mortality
- Overall 90-day mortality
- 34.7%
- Did not differ across settings
- P = 0.345
- Age and SAPS II independently associated with mortality
Appropriate empirical antimicrobial therapy and 90-day survival
- Not associated with improved 90-day survival
- P = 0.128
Original publication
Clinical landscape and mortality risk in Intensive Care Unit peritonitis in a low-MultiDrug Resistant setting: A multicentre cohort study. Anaesth Crit Care Pain Med. Published 26 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →